Clinical trial update: Assiut University has announced a new research initiative studying cortical excitability and the impact of non-invasive repetitive transcranial magnetic stimulation (rTMS) on ADHD and Autism. As of January 12, 2026, recruitment is not yet underway. This trial offers new hope for understanding innovative approaches in neurodevelopmental disorders.
What is the aim of this study?
This upcoming clinical trial is designed to evaluate the effect of active and sham repetitive transcranial magnetic stimulation (rTMS) devices on individuals with Attention Deficit Hyperactivity Disorder (ADHD) and Autism. The study centers on cortical excitability—a measure of brain responsiveness—and the effectiveness of rTMS as a non-invasive tool.
By targeting neurodevelopmental disorders, researchers hope to provide critical insights for medical professionals and device developers. ADHD and Autism affect millions globally, making this trial a significant step toward accessible and effective neurological interventions.
How is the study structured?
The trial, sponsored by Assiut University, incorporates two interventions:
- Active rTMS Device: Participants will receive treatment sessions using the active, repetitive transcranial magnetic stimulation device.
- Sham rTMS Device: To establish controlled comparison, other participants will undergo sessions using the sham (inactive) device.
Recruitment is currently listed as “not yet recruiting.” Clinical teams, sponsors, and regulators are encouraged to watch for updates to assess eligibility or involvement opportunities. Future findings are expected to influence device manufacturing and regulatory pathways.
What are the expected outcomes?
The study seeks to explore how rTMS can regulate and improve cortical excitability in individuals affected by ADHD and Autism. Evidence-based data generated through such trials could pave the way for new device approvals and expand treatment options.
Possible outcomes include:
- The development of non-invasive therapeutic devices tailored for neurodevelopmental disorders.
- Enhanced understanding of safe, effective, and repeatable protocols for using rTMS devices.
- A refined approach to addressing regulatory concerns surrounding neurostimulation technologies.
Manufacturers and clinical teams may find the results highly relevant for device innovation and deployment.
FAQ
1. Who is sponsoring this clinical trial?
The study is sponsored by Assiut University.
2. Are recruitment efforts underway?
Recruitment is currently listed as “not yet recruiting” as of January 12, 2026.
3. What interventions are being tested?
The trial uses active rTMS and sham rTMS devices to evaluate their impact on ADHD and Autism.
4. Where can details about this trial be found?
You can access more information through the link provided at the end of this article.
Conclusion
This upcoming trial signifies critical advancements in understanding ADHD and Autism using cutting-edge brain stimulation devices. Investigators, healthcare providers, and device developers should monitor progress and leverage learnings for future innovations. Stay tuned for regulatory and clinical updates as recruitment begins.
Disclaimer
This article provides information based on published clinical trial data and medical device regulations. It does not serve as legal advice. Always consult regulatory specialists for compliance guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07315217?term=medical+device